Skip to main content
    G

    Galectin Therapeutics Inc (GALT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.02
    -0.03 (-0.98%)

    Market Cap: $307.59M

    Last updated: Nov 17, 2026 at 11:02 AM ET

    Galectin Therapeutics Inc (GALT) Financials: Revenue, Profit and Cash Flow

    Updated Nov 13, 2026. Financial statements from company filings, amounts in US dollars.

    Galectin Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$30.84M, operating cash flow was -$23.88M and free cash flow was -$23.88M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$3.53M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $20.09M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Dec 2018$0N/AN/AN/AN/A
    Dec 2017$0N/AN/AN/AN/A
    Dec 2016$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Research and development$14.29M$36.57M$32.13M$31.74M$23.82M$17.98M$7.47M$6.47M$11.72M$15.32M
    Operating income-$20.09M-$42.43M-$38.07M-$38.35M-$30.18M-$23.44M-$13.44M-$13.60M-$16.25M-$21.48M
    Net income-$30.84M-$47.05M-$41.07M-$38.78M-$30.53M-$23.46M-$13.29M-$13.90M-$16.23M-$21.44M
    EBITDAN/A-$41.81MN/A-$37.76M-$30.00M-$23.41M-$13.40M-$13.60M-$16.25M-$21.47M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$0$0$0$0$0$0$36.00K$0$0$0$80.00K
    Gross profit$0$0$0$12.00K$0$0$0-$10.00K$0$0$0-$9.00K
    Operating income-$3.37M-$3.98M-$4.08M-$3.37M-$4.20M-$4.63M-$7.90M-$12.43M-$9.07M-$11.29M-$9.65M-$9.56M
    Net income-$3.53M-$9.11M-$5.05M-$5.50M-$8.18M-$7.52M-$9.63M-$11.97M-$11.22M-$12.37M-$11.49M-$10.00M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of $133.74M exceeded cash and equivalents by $116.02M. Shareholder equity was negative, at -$127.92M, as total liabilities of $145.73M exceeded total assets of $19.53M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$19.53M$17.50M$28.20M$21.29M$41.83M$29.60M$48.47M$9.01M$4.16M$15.79M
    Current assets$19.44M$17.25M$27.71M$20.55M$41.82M$29.46M$48.21M$8.83M$3.82M$15.79M
    Cash and equivalents$17.72M$15.12M$25.66M$18.59M$39.65M$27.14M$47.48M$8.25M$3.05M$15.36M
    Total liabilities$145.73M$120.56M$88.44M$53.48M$39.21M$5.41M$2.87M$2.11M$2.97M$3.78M
    Short-term debt$0$21.12M$0$40.00K$8.00K$44.00K$39.00KN/AN/AN/A
    Long-term debt$133.74M$85.11M$71.74M$9.86M$29.05M$0N/AN/A$0$0
    Shareholder equity-$127.92M-$104.79M-$61.96M-$33.92M$893.00K$22.47M$43.87M$5.17M-$530.00K$10.29M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$13.01M$14.83M$15.76M$19.53M$12.87M$15.60M$9.53M$17.50M$28.97M$27.66M$25.89M$28.20M
    Total liabilities$46.45M$151.68M$146.00M$145.73M$136.44M$132.77M$121.79M$120.56M$121.45M$109.80M$96.98M$88.44M
    Cash and equivalents$11.71M$13.27M$14.11M$17.72M$11.53M$13.77M$7.43M$15.12M$27.06M$25.60M$23.55M$25.66M
    Shareholder equity-$35.16M-$138.57M-$131.96M-$126.19M-$125.30M-$118.89M-$113.98M-$103.07M-$94.20M-$83.87M-$72.81M-$60.24M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$23.88M-$41.77M-$32.97M-$31.06M-$24.31M-$20.60M-$10.85M-$10.18M-$15.89M-$16.41M
    Free cash flow-$23.88M-$41.77M-$32.97M-$31.06M-$24.31M-$20.60M-$10.85M-$10.18M-$15.89M-$16.41M
    Dividends paid$138.00K$91.00K$120.00K$97.00K$171.00K$137.00K$394.00K$0$1.23M$741.00K
    Financing cash flow$26.48M$31.23M$40.03M$10.00M$36.81M$263.00K$50.08M$15.38M$3.58M$5.92M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$2.27M-$2.44M-$3.87M-$6.04M-$3.54M-$6.60M-$7.69M-$12.79M-$8.54M-$8.33M-$12.11M-$4.70M
    Free cash flowN/AN/A-$3.87M-$6.04M-$3.54M-$6.60M-$7.69M-$12.79M-$8.54M-$8.33M-$12.11M-$4.70M
    Last 12 quarters

    Frequently Asked Questions About GALT

    What is Galectin Therapeutics' annual revenue?

    Galectin Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Galectin Therapeutics profitable?

    No. Galectin Therapeutics reported net income of -$30.84M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does GALT generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$23.88M minus capital expenditures of $0 produced free cash flow of -$23.88M.

    How much debt does Galectin Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $133.74M, short-term debt of $0 and cash and equivalents of $17.72M.